Microdystrophin AAV Dosing for Efficacy and Immune Response Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for treating dystrophinopathies, such as Duchenne and Becker muscular dystrophy, are limited by the need for effective administration of AAV vectors encoding microdystrophins while minimizing immune responses and ensuring therapeutic efficacy.

Innovation Solution

Administration of rAAV particles encoding a microdystrophin protein with specific domains (ABD-H1-R1-R2-R3-H3-R24-H4-CR-CT) at doses of 5×10^13 to 1×10^15 genome copies/kg, optionally with immunosuppressants, to treat dystrophinopathies, improving muscle and cardiac function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Strength

If AAV vectors encoding microdystrophin are administered to treat dystrophinopathies, then muscle strength and function are improved, but immune responses may occur

Engineering Contradiction:

Improvemuscle strengthVSAvoidimmune responses

Core Design Contradiction:

StrengthVSObject-affected harmful factors

Solution Approach 1:

The patent segments the dystrophin protein into a microdystrophin version containing only essential domains (ABD-H1-R1-R2-R3-H3-R24-H4-CR-CT), reducing the protein size to fit within AAV vector payload limits while maintaining therapeutic function. This segmentation allows effective treatment without requiring full-length dystrophin expression

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent optimizes the AAV vector dosage parameters, administering 5×10^13 to 1×10^15 genome copies/kg to achieve therapeutic efficacy while managing immune response risks. The specific dosage range balances sufficient microdystrophin expression with minimized immune activation

Inventive Principle:

Principle #35Parameter changes

2Reliability

If AAV vectors are administered at high doses to ensure therapeutic efficacy, then treatment effectiveness is improved, but immune responses and safety concerns increase

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidimmune responses

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent establishes a specific dosage range (5×10^13 to 1×10^15 genome copies/kg) that optimizes the balance between therapeutic efficacy and immune response minimization. This parameter optimization ensures reliable treatment effectiveness while controlling safety concerns at higher doses

Inventive Principle:

Principle #35Parameter changes

3Strength

If full-length dystrophin is expressed to treat dystrophinopathies, then muscle function is improved, but the AAV vector payload size is exceeded

Engineering Contradiction:

Improvemuscle functionVSAvoidvector payload size

Core Design Contradiction:

StrengthVSLength of moving object

Solution Approach 1:

The patent divides the full-length dystrophin protein into a segmented microdystrophin version containing only essential functional domains. This segmentation reduces the protein size from full-length to approximately 1.5 kb, enabling it to fit within the AAV vector payload capacity while preserving therapeutic muscle function

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent extracts and removes non-essential domains from the full-length dystrophin protein, retaining only the critical functional regions (ABD-H1-R1-R2-R3-H3-R24-H4-CR-CT). This extraction creates a minimized version that fits vector constraints while maintaining therapeutic activity

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS20250312492A1Microdystrophin gene therapy administration for treatment of dystrophinopathies

Publication Date: 2025.10.09 REGENXBIO INC

AI summary

Provided are methods of treating or ameliorating the symptoms of dystrophinopathies, such as Duchenne muscular dystrophy and Becker muscular dystrophy by administration of therapeutically effective doses of recombinant adeno-associated viruses (rAAV) containing a transgene encoding a microdystrophin.